Kiwi Medical Science Breakthrough to Heal US Wounds
Chitogel’s wound-healing gel gets FDA approval for sinus surgery
WELLINGTON, New Zealand, 7 November 2017 - A ground-breaking wound-healing gel developed by NZ medical science company
Chitogel will be used to treat sinus patients in the United States now that that regulatory clearance from the US Food
and Drug Administration (FDA) has been approved.
Chitogel represents a significant medical advancement to endoscopic sinus surgery, which is one of the most common
surgical procedures globally, and is performed approximately 500,000 times each year in the US.
The company’s eponymous gel is the only topical medical treatment in the world that has been scientifically proven to
significantly reduce bleeding, and almost completely eliminate scarring resulting from sinus operations*. This is
significant given 15 % of sinus surgeries need to redone due to complications arising from bleeding, scarring and
infection.
Further, applying the clear gel dressing within the sinus cavity after surgery replaces the need for gauze bandages to
be used, thereby improving a patient’s comfort during recovery.
With FDA approval, Chitogel can now move forward with its plans to capture 20-30% of the US market by the end of 2020.
The US will be the first market to receive commercial shipments of the gel, which is produced at the company’s new
manufacturing plant at Callaghan Innovation’s Gracefield Science Quarter in Wellington.
Chair Phil Royal says he expects the first bulk commercial shipments of Chitogel to be exported by the middle of next
year, and notes pharmaceutical companies are currently trialling the product as part of advanced negotiations on
potential distribution agreements.
“This FDA clearance represents a huge milestone for our young company and the medical world”, says Mr Royal. “Outcomes
for surgeons and their patients will be significantly improved by using Chitogel, which has been developed over the
course of the past 12 years using innovative Kiwi research and technology.
“It’s a very exciting time for the advancement of ear, nose and throat surgeries.”
Mr Royal acknowledges the many years of hard work leading up to the FDA milestone. This includes developing partnerships
with Callaghan Innovation, the New Zealand government, world-leading clinicians, and some of the best scientists in New
Zealand.
Other uses and markets:
With FDA approval to use Chitogel as a medical device for sinus surgeries, the company will next be submitting
applications to secure FDA clearance for post-surgery use in spinal and abdominal surgeries, once extensive testing of
the these products is complete. The company will also look to seek regulatory clearance in other markets beyond the US.
The early brains behind Chitogel
Chitogel’s early development was the brainchild of two award-winning researchers: the late New Zealand chemical
scientist, Marsden medallist, and Otago University Professor Brian Robinson, who was Chitogel’s previous Chair before he
passed away last year; and the University of Adelaide’s Professor PJ Wormwald, who is one of the world’s foremost Ear,
Nose and Throat surgeons.
ENDS
About Chitogel Ltd (pronounced kyto-gel)
Chitogel produces an eponymous clear topical medical gel which has been scientifically proven to provide cost-effective
wound healing solutions that significantly reduce the bleeding, scarring and infection resulting from sinus operations.
The company maintains an extensive portfolio of patents covering innovative treatments based on a formula involving
highly complex carbohydrate chemistry.
Initially developed by researchers at Otago and Adelaide universities, Chitogel opened a manufacturing plant near
Wellington, New Zealand in 2016, where the gel will be produced and then shipped to the United States. Its
patent-protected formula is made from two chemical compounds: chitosan succinamide, derived from high grade shrimp; and
and dextran aldehyde, a natural sugar polymer. See http://www.chitogel.com/